Last Updated: November 18, 2026

Drug Price Trends for RASAGILINE

« Back to Dashboard


Drug Price Trends for RASAGILINE

Average Pharmacy Cost for RASAGILINE

These are average pharmacy acquisition costs (net of discounts) from a US national survey
Drug Name NDC Price/Unit ($) Unit Date
RASAGILINE MESYLATE 0.5 MG TAB 00093-3060-56 0.57949 EACH 2026-07-22
RASAGILINE MESYLATE 0.5 MG TAB 13668-0447-30 0.57949 EACH 2026-07-22
RASAGILINE MESYLATE 0.5 MG TAB 16714-0770-01 0.57949 EACH 2026-07-22
RASAGILINE MESYLATE 0.5 MG TAB 23155-0746-03 0.57949 EACH 2026-07-22
RASAGILINE MESYLATE 0.5 MG TAB 33342-0308-07 0.57949 EACH 2026-07-22
RASAGILINE MESYLATE 0.5 MG TAB 42571-0220-30 0.57949 EACH 2026-07-22
RASAGILINE MESYLATE 0.5 MG TAB 47781-0683-30 0.57949 EACH 2026-07-22
>Drug Name >NDC >Price/Unit ($) >Unit >Date

Best Wholesale Price for RASAGILINE

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available to any customer under comparable terms and conditions
Drug Name Vendor NDC Count Price ($) Price/Unit ($) Unit Dates Price Type
RASAGILINE MESYLATE 1MG TAB AvKare, LLC 42291-0780-30 30 46.64 1.55467 EACH 2023-06-15 - 2028-06-14 FSS
RASAGILINE MESYLATE 0.5MG TAB AvKare, LLC 42291-0779-30 30 39.51 1.31700 EACH 2023-06-15 - 2028-06-14 FSS
>Drug Name >Vendor >NDC >Count >Price ($) >Price/Unit ($) >Unit >Dates >Price Type
Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

RASAGILINE market analysis and price projections: exclusivity, generic entry risk, and revenue outlook

Last updated: July 9, 2026

Rasagiline has a mature, largely generic-exposed market in most jurisdictions. Pricing trends are dominated by (1) patent and exclusivity end dates for branded products, (2) geographic penetration of generics and local incumbents, and (3) payer switching behavior after first generic launches. A defensible price projection requires mapping exact country-level brand incumbency, Orange Book or equivalent listings, and realized generic shares by strength/formulation. Those inputs are not provided.

H2: What is the current market size and unit demand for rasagiline by geography?
No sufficient jurisdiction-specific or sales-volume data is available in the prompt to produce a market-size or unit-demand split by geography.

H2: How are rasagiline prices trending in the US, EU5, and UK after generic launches?
No sufficiently sourced price history, payer net-price trajectories, or product-specific ASP/WAC series are available in the prompt to quantify US/EU/UK trendlines.

H2: What patent estate protects rasagiline and when does it expire?
No patent numbers, expiration dates, or jurisdictional coverage are included in the prompt. Without an explicit patent and exclusivity dataset, an expiration timeline cannot be calculated.

H2: When does rasagiline lose exclusivity for branded tablets in major markets?
No FDA Orange Book or equivalent exclusivity dates (including non-patent exclusivity, if any) are provided. A loss-of-exclusivity calendar cannot be generated from the current inputs.

H2: What patent litigation affects rasagiline generic entry, including Paragraph IV challenges?
No litigation docket references, settlement agreements, or Paragraph IV filings are provided. A litigation-driven generic timing scenario cannot be constructed.

H2: What is the Orange Book status of rasagiline and which patents are listed?
No Orange Book listing data (application numbers, listed patents, active ingredients, dosage forms, expiration dates) is provided. Status and listing counts cannot be computed.

H2: Which companies are challenging rasagiline and what settlement terms exist?
No challenger identities, ANDA filers, or settlement terms are included. A competitive filing map cannot be produced.

H2: What formulations are protected for rasagiline (tablet strength, polymorph, process), and how does that affect generic pricing?
No formulation-level patenting details (strength-specific claims, polymorph/process patents, bioequivalence constraints) are provided. Without that, formulation-constraint-driven pricing effects cannot be modeled.

H2: How strong is the patent estate for rasagiline across the US and Europe?
No patent family structure, claim scope, prosecution history, or enforcement history is available in the prompt. Patent-strength scoring is not possible.

H2: How does rasagiline compare with competing Parkinson’s disease therapies on pricing pressure?
No competitor list, relative share, or therapeutic interchangeability evidence is provided. Comparative pricing leverage cannot be quantified.

H2: What generic entry risks exist for rasagiline and how fast do prices fall after launch?
No generic launch dates, market-share trajectories, or historical price erosion curves are provided. A post-entry price-fall model cannot be built from the current inputs.

H2: What manufacturing or IP barriers could delay rasagiline generics and sustain branded pricing?
No manufacturing-process IP, supplier constraints, or regulatory/CMC contingencies are provided.

H2: What is the biosimilar risk for rasagiline?
Rasagiline is a small molecule, so biosimilar risk is not applicable; no supporting dataset is needed.

H2: How do payer formularies and prior authorization affect rasagiline net price?
No formulary status, rebate dynamics, or utilization management specifics are provided.

H2: Price projections for rasagiline: base, bull, and bear cases by year
A numeric projection cannot be produced without at least: (1) current branded price and generic penetration baseline by country, (2) forecast of generic launch timing, and (3) patent/exclusivity expiration dates driving entry. Those inputs are not provided.

Key Takeaways

  • Rasagiline’s market economics are primarily driven by generic penetration timing and patent/exclusivity calendars by jurisdiction.
  • The prompt does not include the patent, Orange Book/registry, litigation, or country-level price and volume inputs required to generate hard year-by-year price projections.

FAQs

  1. Does rasagiline face biosimilar competition?
    Rasagiline is a small molecule, so biosimilars are not the relevant substitution path.

  2. What determines whether rasagiline pricing holds or drops after first generic entry?
    Time since launch, generic share ramp speed, and payer switching behavior.

  3. What role do dosage form and strength play in rasagiline generic entry risk?
    Strength-specific product availability and any strength-linked formulation/process patents can affect launch timing.

  4. How does patent litigation typically change rasagiline generic launch timing?
    Settlements and injunctions can delay entry even when ANDAs are filed.

  5. Which markets usually see the fastest rasagiline price erosion?
    Markets with earlier generic launches and higher reimbursement switching intensity, but the exact ranking cannot be determined from the provided inputs.

References (APA)

  1. No sources were provided in the prompt, and no external citation set is available to support specific market sizing, price histories, exclusivity dates, or litigation facts.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.